HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma

5Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Human leukocyte antigen-E (HLA-E) has been putatively associated with the pathogenesis of multiple myeloma (MM). Our study first showed that HLA-E was differentially expressed on MM and normal plasma cells (39.27 ± 27.01 and 11.28 ± 0.79, respectively). Based on the median value of HLA-E expression, we further stratified MM patients into high and low-expression groups, and then found high expression of HLA-E was correlated with advanced ISS stage (p = 0.025) and high-risk cytogenetics risk stratification (p = 0.000) by the Pearson Chi-square test, suggesting that HLA-E could be considered as a biomarker for high-risk MM. Furthermore, peptide 3 (P3) from our previous study was confirmed to possess a high affinity to HLA-E positive MM cells. Taken together, HLA-E could be considered as a new marker and candidate treatment target for MM, while peptide P3 may act as a potential treatment choice for targeting MM cells.

Cite

CITATION STYLE

APA

Yang, Y., Liu, Z., Wang, H., & Zhang, G. (2021). HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.670673

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free